Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2025-03-31): -175.70%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alps Group Inc
Market Cap
$66.56M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$67.11M
Return on Invested Capital (ROIC)
-3699.99%
TTM Avg
-104.88%
3Y Avg
-89.50%
5Y Avg
-74.29%
Market Cap
$65.08M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-86.10%
3Y Avg
-83.22%
5Y Avg
-74.34%
Market Cap
$64.56M
Return on Invested Capital (ROIC)
-4.72%
TTM Avg
-4.96%
3Y Avg
-2.45%
5Y Avg
-3.32%
Market Cap
$69.05M
Return on Invested Capital (ROIC)
-6.75%
TTM Avg
20.47%
3Y Avg
-36.30%
5Y Avg
-23.36%
Market Cap
$63.98M
Return on Invested Capital (ROIC)
-83.74%
TTM Avg
-153.15%
3Y Avg
-164.21%
5Y Avg
-165.99%
Market Cap
$69.43M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
Market Cap
$70.01M
Return on Invested Capital (ROIC)
-153.46%
TTM Avg
-63.13%
3Y Avg
-47.00%
5Y Avg
-35.71%
Market Cap
$70.03M
Return on Invested Capital (ROIC)
-6.79%
TTM Avg
-4.87%
3Y Avg
-47.70%
5Y Avg
-62.00%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $66.56M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | -3699.99% | -104.88% | -89.50% | -74.29% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | N/A | -86.10% | -83.22% | -74.34% |
| InterCure Ltd. (INCR)vs › | $64.56M | -4.72% | -4.96% | -2.45% | -3.32% |
| Champions Oncology, Inc. (CSBR)vs › | $69.05M | -6.75% | 20.47% | -36.30% | -23.36% |
| Cingulate Inc. (CING)vs › | $63.98M | -83.74% | -153.15% | -164.21% | -165.99% |
| Fortress Biotech, Inc. (FBIO)vs › | $69.43M | -10.85% | -101.00% | -120.85% | -96.47% |
| MindWalk Holdings Corp. (HYFT)vs › | $70.01M | -153.46% | -63.13% | -47.00% | -35.71% |
| Heron Therapeutics, Inc. (HRTX)vs › | $70.03M | -6.79% | -4.87% | -47.70% | -62.00% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | -52.40% | -44.92% | -44.92% | -44.02% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-03-31 | -175.70% |
| 2024-12-31 | -116.62% |
| 2024-09-30 | -6.25% |
